管理难治性免疫检查点相关毒性的新治疗视角
本文总结免疫检查点抑制剂所致严重及难治性免疫相关不良事件的治疗策略,基于发病机制讨论新型生物与非生物免疫抑制药物,并根据优势免疫浸润类型提出超越常规糖皮质激素的个体化管理治疗算法及「关闭」策略。
要点
- 免疫检查点抑制剂带来新毒性谱,严重难治性免疫相关不良事件是治疗挑战。
- 基于发病机制,可选用新型生物与非生物免疫抑制药物治疗类固醇难治性事件。
- 作者提出根据优势免疫浸润类型的个体化治疗算法及「关闭」策略。
核心结论
- 作者提出「关闭」策略,旨在抑制免疫相关不良事件病理生理过程中的关键炎症组分,并限制药物免疫抑制对肿瘤反应的潜在不良影响。
研究设计与样本
- 本文为个人观点(Personal View)文章,总结用于管理免疫检查点抑制剂治疗所致毒性的治疗策略。
主要发现
- 基于当前对免疫相关不良事件发病机制的认识,讨论了使用新型生物和非生物免疫抑制药物治疗严重且类固醇难治性免疫相关不良事件。
- 根据占优势的免疫浸润类型,提出了超越典型糖皮质激素使用的个体化管理治疗算法。
临床怎么用
- 作者提出的治疗算法根据优势免疫浸润类型进行个体化管理,超越典型糖皮质激素的使用。
- 作者提出的「关闭」策略在现有指南基础上发展,并对逐步增加药物免疫抑制的方法提出挑战。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors are reshaping the prognosis of many cancer and are progressively becoming the standard of care in the treatment of many tumour types. Immunotherapy is bringing new hope to patients, but also a whole new spectrum of toxicities for healthcare practitioners to manage. Oncologists and specialists involved in the pluridisciplinary management of patients with cancer are increasingly confronted with the therapeutic challenge of treating patients with severe and refractory immune-related adverse events. In this Personal View, we summarise the therapeutic strategies that have been used to manage such toxicities resulting from immune checkpoint inhibitor treatment. On the basis of current knowledge about their pathogenesis, we discuss the use of new biological and non-biological immunosuppressive drugs to treat severe and steroid refractory immune-related adverse events. Depending on the immune infiltrate type that is predominant, we propose a treatment algorithm for personalised management that goes beyond typical corticosteroid use. We propose a so-called shut-off strategy that aims at inhibiting key inflammatory components involved in the pathophysiological processes of immune-related adverse events, and limits potential adverse effects of drug immunosuppression on tumour response. This approach develops on current guidelines and challenges the step-by-step increase approach to drug immunosuppression.
引用
- Martins F, Sykiotis GP, Maillard M, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019. PMID: 30614479. doi:10.1016/S1470-2045(18)30828-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。